Spero therapeutics provides business update and announces interim leadership changes

Esther rajavelu appointed interim president and chief executive officer, frank thomas appointed chairman of the board interim changes to leadership follow the company's response to a wells notice from the sec relating to certain public disclosures made in 2022 phase 3 pivot-po trial of tebipenem hbr reaches over 60% enrollment as of december 31, 2024; remains on track to complete enrollment in 2h 2025 cash balance and cash runway guidance remains into mid-2026 cambridge, mass., jan. 10, 2025 (globe newswire) -- spero therapeutics, inc. (“spero” or the “company”) (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today provided a corporate update regarding interim changes to its leadership and board as well as an enrollment update regarding the phase 3 pivot-po trial of tebipenem hbr.
SPRO Ratings Summary
SPRO Quant Ranking